Acadia misses mark in Alzheimer’s but concludes phase 3 ‘absolutely worth’ pursuing
Acadia Pharmaceuticals' phase 2 Alzheimer's trial missed its primary endpoint but showed encouraging signals. The 60-mg dose of remlifanserin reduced hallucinations and delusions by 12.6 points vs. 10.4 on placebo. Analysts and the company see potential for phase 3, citing safety and efficacy. Acadia's stock dropped 11% to $22.50 on the news.
How this was made
The 30-second read
Why it matters
The Phase 2 miss introduces uncertainty for the upcoming Phase 3 trial but retains optimism due to safety data and a nominally significant secondary endpoint.
Market read
The trial result is a primary catalyst for ACAD, driving an immediate 11% price drop and influencing investor sentiment in the CNS‑therapeutics space.
What to watch
Potential enrollment enrichment for Phase 3 may improve effect size; competitors lack a QT‑safe option.
Background
Acadia Pharmaceuticals (NASDAQ: ACAD) is developing remlifanserin for Alzheimer’s disease psychosis, a follow‑on to its approved drug Nuplazid.
Ticker impact
Acadia Pharmaceuticals missed the primary endpoint in its Phase 2 Alzheimer’s psychosis trial, causing the stock to open down 11%.
Short-term pressure likely; price may test support around $22 before stabilizing.
The miss is material for a biotech; however, the near‑significant p‑value and safety profile keep upside potential for Phase 3.
Market effects
Alzheimer’s and psychosis biotech sector may see heightened scrutiny of trial designs.
US biotech indices could dip slightly as the news spreads.
Limited to investors tracking CNS‑focused drug pipelines.
Counterpoint
The safety profile and secondary endpoint success could make the stock a buy on pull‑back.
Key entities
- companyAcadia Pharmaceuticals
Biotech developing remlifanserin for Alzheimer’s psychosis.
- executiveCatherine Owen Adams
CEO of Acadia, expressed confidence in Phase 3 plans.
